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Objectives This study sought to compare the 1-year safety and efﬁcacy of Cypher Select or Cypher Select
Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-
metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients.
Background There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR.
Methods The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter
and international registry encompassing virtually all subsets of patients and lesions treated with at
least 1 SES during the period from 2006 to 2008. We enrolled in this pre-speciﬁed subanalysis all
patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was
major adverse cardiac events and stent thrombosis rate at 1 year.
Results Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n  1,235,
DES group, n  355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%,
p  0.001), renal insufﬁciency (5.8% vs. 2.3%, p  0.003), and prior coronary artery bypass graft
(20.5% vs. 11.8%, p  0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p  0.3) and myocar-
dial infarction (2.4% for BMS and 3.3% for DES, p  0.3) rates were similar, whereas ische-
mia-driven target lesion revascularization and deﬁnite/probable late stent thrombosis were higher in
patients with DES ISR (6.9% vs. 3.1%, p  0.003, and 1.8% vs. 0.5%, p  0.04, respectively).
Conclusions Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion
revascularization recurrence and no apparent safety concern. (J Am Coll Cardiol Intv 2012;5:64–71) © 2012
by the American College of Cardiology Foundation
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65Excessive neointimal growth leading to in-stent restenosis
(ISR) has been the major drawback of percutaneous coro-
nary intervention, occurring in up to 25% to 30% of the
cases treated with bare-metal stents (BMS).
From balloon angioplasty and atherectomy to intravascu-
lar brachytherapy (IVB), many alternative strategies were
investigated as treatment options in this challenging scenario
1–4). However, none of them achieved the expected efficacy
nd safety profile and, in some cases, the logistical demands
recluded the worldwide acceptance of the strategy.
With their efficacy and superiority over BMS demon-
trated in a variety of complex clinical and angiographic
ettings (5–7), drug-eluting stents (DES) were rapidly incor-
orated into clinical practice and became the treatment of
hoice for difficult situations, including BMS ISR (8–10).
Although infrequent, DES ISR still occurs, and the best
pproach to treat it is yet to be defined. Using data from the
-SELECT (Multicenter Post-Market Surveillance) registry, a
arge, prospective and observational registry of patients who
nderwent implantation of sirolimus-eluting stents (SES), we
imed to determine 1-year efficacy and safety of Cypher Select
r Cypher Select Plus (Cordis Corporation, Bridgewater, New
ersey) SES for the treatment of previous BMS and DES ISR
n complex patients treated in routine daily practice.
ethods
The present study represents a pre-specified subanalysis
of the prospective, international e-SELECT registry. De-
tails of this registry have been published (11) elsewhere. In
brief, e-SELECT was conducted at 320 medical centers
(listed in the Online Appendix) in 56 countries where SES
were approved for commercial use. Baseline data were
collected between May 2006 and April 2008 in consecutive
and eligible patients who underwent implantation of 1
Cypher Select or Cypher Select Plus SES according to
standard clinical practice and procedural techniques. It is
important to note that both SES have the same polymer and
amount of antiproliferative drug (with identical kinetic
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accepted September 7, 2011.release profile). Cypher Select or Cypher Select Plus only
differs in the platform design, because there were slight
modifications in the latest one to enhance flexibility and
deliverability.
The protocol specified very few inclusion or exclusion
criteria. Lesions could be pre-treated with any technique or
device, such as balloon angioplasty, cutting balloon, or atherec-
tomy, but implantation of SES in each target lesion during the
index procedure was mandatory. All post-operative medical
management, including antithrombotic therapy, was pre-
scribed according to usual local practice. The protocol was
approved by the ethics committee of each participating center
and the patients granted their consent to participate in the registry.
Patients for whom the collection of dependable follow-up infor-
mation was unlikely and those who received a stent other than a
SES during the index procedure were excluded.
For the present study, we included all patients with at
least 1 BMS or DES ISR treated
with percutaneous coronary in-
tervention and SES deployment.
We defined ISR as 50% an-
giographic stenosis within or 5
mm proximal and distal to the
stent.
Data collection and management.
The data collected by the
e-SELECT registry include de-
mographic information, cardio-
vascular history, comorbidity, le-
sion and procedure characteristics,
and antithrombotic regimens. Pa-
tients were followed at 30, 180,
and 360 days by telephone com-
munication, office visit, or by con-
tacts with primary physicians or
referring cardiologists.
The data were collected elec-
tronically at each participating center and transferred to an
independent data management organization (KIKA Medi-
cal, Nancy, France). After verification of their consistency,
the data were analyzed by an independent clinical research
organization (Cardialysis, Rotterdam, the Netherlands).
The accuracy of data collection was monitored by an
independent organization (Covance, Princeton, New Jersey)
in 20% of the overall sample, at 100 centers selected by a
stratification scheme based on patient enrollment, region of
the world, and rate of data outliers. The consistency and
accuracy of data contained in the source documentation
versus that entered in the electronic database were verified
using an anonymous procedure to preserve confidentiality.
The data were “consistent” when present in both the source
documents and in the electronic database and “accurate”
when the electronic database fully matched the data entered
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
HR  hazard ratio
ISR  in-stent restenosis
IVB  intravascular
brachytherapy
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularizationin the source documents. Using these definitions, overall
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66data consistency was 99%. The accuracy of baseline data was
96%, and that of adverse events recorded during follow-up
was 93.2%.
Study endpoints. The primary objective of this subanalysis
was the comparison of major adverse cardiac events (MACE)
and stent thrombosis (ST) at 1-year clinical follow-up of
patients with BMS or DES ISR treated with a SES.
MACE were defined as cardiac death, myocardial infarc-
tion (MI), and target lesion revascularization (TLR). All
deaths were considered cardiac unless a noncardiac origin
could be clearly established by clinical and/or pathological
study. The diagnosis of MI was based on either the
development of new pathological Q waves in2 contiguous
electrocardiogram leads and/or post-procedure elevation of
creatine kinase-myocardial band isoenzyme 3 times the
upper normal limit during index hospitalization, or cardiac
enzyme elevation 2 times the upper normal limit thereaf-
ter. TLR was considered clinically driven when it was
prompted by symptoms and/or signs of ischemia.
Stent thrombosis was classified as definite, probable, and
possible according to definitions proposed by the Academic
Research Consortium and was stratified as acute (24 h),
subacute (24 h to 30 days), and late (1 to 12 months).
Procedural success was defined as angiographic success
plus absence of MACE during hospitalization.
Study organization and supervision. A steering committee
planned the analysis, presentations, and publications of
registry data. The algorithms used to classify clinical events
and the criteria used for the adjudications of MACE were
developed by a Clinical Event Committee composed of
interventional cardiologists who were not associated with
the sponsor and were not participants in the registry. The
committee adjudicated all MACE, deaths, ST, and MI by a
systematic review of the data collection forms and by review
of the source documents, electrocardiograms, and angio-
grams, when necessary. Routine angiographic follow-up was
not part of the study protocol.
Statistical analysis. For all patients, standard descriptive
statistics were used for baseline, lesion, and procedural
characteristics and for clinical results. Continuous variables
are presented as mean  SD or medians and range, and
compared using Student t test, whereas categorical variables
are presented as numbers and percentages and compared
using chi-square test. When the assumptions were broken,
Fisher exact test was used.
Cumulative rates of adverse clinical events were calculated
using event-specific adjusted denominators, so that all
patients suffering an event within 360 days, or followed up
for at least 330 days after the index procedure, contributed
to the denominator. There was no censoring. Kaplan-Meier
curves and time-to-event summaries were constructed, us-
ing the life-table method, to examine the long-term inci-
dence of clinical and safety endpoints. Predictors of major
clinical safety endpoints were identified by univariate andmultivariate analyses using Cox proportional hazards model.
For each outcome endpoint, baseline covariates identified by
the univariate analysis (p  0.05), by the proportional
hazards assumption test (p  0.05 combined with graphic
assessment), and by clinical relevance were included in the
multivariate model stepwise selection procedure. An entry
criterion probability value of 0.10 and a stay criterion of 0.05
were used and baseline covariates with15% missing values
were excluded from analysis. No missing value imputation
was performed. All statistical analyses were performed with
SAS software (version 9.1 or higher, SAS Institute, Cary,
North Carolina).
Results
The e-SELECT database registered 15,400 patients, 253 of
whom were deregistered after online data queries and on-site
monitoring of source data, resulting in a sample of 15,147
patients who were compliant with the inclusion/exclusion
criteria specified in the protocol. Among them, 1,590 (10.5%)
patients had 1 or more ISR as the index procedure target
lesions. These patients were divided in 2 groups according to
the type of stent that resulted in the restenotic lesion (BMS
group, n  1,235; DES group, n  355).
Patients with DES ISR had significantly more comor-
bidity, as shown by a higher incidence of diabetes (39.4% vs.
26.9%, p  0.001), renal insufficiency (5.8% vs. 2.3%, p 
0.003), and Charlson index 3 (20.0% vs. 13.1%, p 
0.002). Of note, acute coronary syndrome was frequently
the initial manifestation of ISR for both BMS (43.5%) and
DES (44.2%, p  0.81), with more than 10% of ST-
segment elevation MI in each cohort (10.2% in BMS ISR
vs. 13% in DES ISR, p  0.15). Table 1 contains the
detailed baseline clinical characteristics.
Overall, the lesion per patient rate was 1.11, with significant
difference between groups (1.07 lesion/patient in the DES
cohort vs. 1.12 lesion/patient in the BMS population, p 
0.011). A diffuse restenosis pattern (20 mm) was more
frequent in the BMS group than in the DES group (55.7% vs.
42.2%, p  0.001). Mean estimated lesion length was signif-
icantly longer in the BMS group (22.5 12.4 vs. 19.3 11.1,
p 0.001) but with a stented length/lesion length ratio similar
between groups (1.40 in the BMS vs. 1.36 in the DES, p 
0.37). The estimated reference vessel diameter was also equiv-
alent between groups (2.99 0.42 mm in the DES cohort vs.
3.00  0.43 mm in the BMS group, p  0.71). Detailed
procedure characteristics are displayed in Table 2.
A total of 88.2% (1,089 of 1,235 of the patients from the
BMS ISR group) and 91.3% (324 of 355) from the DES ISR
cohort completed the 12-month clinical follow-up (p  0.1).
At 1 year (Table 3), the incidence of death (1.4% for BMS vs.
2.1% for DES, p 0.3) and MI (2.4% for BMS and 3.3% for
DES, p  0.3) did not significantly differ between groups.
However, ischemia-driven TLR was higher among patients
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67with previous DES ISR (6.9% vs. 3.1%, p 0.003). Although
there was a trend toward an overall higher rate of definite/
probable ST among patients with DES ISR, this was not
statistically significant (2.4 vs. 1.2, p  0. 12) and was entirely
due to a significantly higher occurrence of late ST among these
subjects (1.8% vs. 0.5%, p  0.04) (Table 4).
Figures 1 and 2 show the Kaplan-Meier survival curve
free of MACE, death, MI, and TLR of the 3 treatment
populations in comparison included in the e-SELECT
registry. It is clear that patients with previous BMS ISR
treated with SES have outcomes very similar to a de novo
lesion population, whereas patients treated for DES ISR
had less favorable outcomes with significantly worse survival
curve free of MACE (Fig. 1) mainly because of a higher
incidence of MI and TLR (Figs. 2B and 2C).
Notably, procedure success and 1-year clinical outcomes
were equivalent for patients successfully treated with either
Cypher Select or Cypher Select Plus SES.
It is important to notice that adherence to dual antiplate-
let regimen was relatively high in both groups. At 6 months,
94.6% and 94.8% of patients in the DES ISR and BMS ISR
cohorts were taking the dual antiplatelet regimen (p 
0.89), whereas at 1 year, 81.5% of the individuals in the
DES ISR group and 83.6% in the BMS cohort (p  0.4)
were taking both medicines.
The independent predictors of MACE following the use of
SES for the treatment of BMS ISR were diabetes mellitus
(hazard ratio [HR]: 2.7 [interquartile range (IQR): 1.6, 4.4],
p  0.001), Charlson comorbidity index (HR: 1.1 [IQR: 1.0,
Table 1. Baseline Clinical Characteristics
Variable
B
(n 
Age
Mean  SD (N) 63.20
Median (min, max) 63.0 (
Male 73.3 (
Diabetes mellitus 26.9 (
Insulin-treated 6.3 (
Hypertension 76.9 (
Hyperlipidemia 81.1 (
Smoking 54.1 (
Renal insufﬁciency, Cr 177 mol/l 2.3 (
Body mass index 30 kg/m2 24.9 (
Charlson comorbidity index 3 13.1 (
Prior CABG 11.8 (
Clinical presentation of unstable angina 33.3 (
Clinical presentation of MI 10.2 (
Left ventricular function 30% 2.3 (
Acute coronary syndrome 43.5 (
Values are % (n/N) unless otherwise noted.
BMS bare-metal stent(s); CABG coronary artery bypass graft; C
MImyocardial infarction.1.1], p  0.001), age (by 10-year increment, HR: 1.5 [IQR:1.1, 1.9], p  0.005), previous coronary artery bypass graft
(HR: 2.2 [IQR: 1.3, 4.0], p  0.006), American College of
Cardiology/American Heart Association lesion morphology
class B2 or C (HR: 2.5 [IQR: 1.3, 4.7], p  0.006), and
multivessel disease (2- or 3-vessel disease, HR: 2.0 [IQR: 1.2,
3.3], p  0.009). Independent predictors of TLR in the same
cohort were diabetes mellitus (HR: 4.6 [IQR: 2.3, 9.3], p 
0.001), bypass graft lesion (HR: 5.1 [IQR: 2.0, 13.2], p 
0.001), any cancer (solid/metastatic/lymphoma/leukemia, HR:
15.7 [IQR: 2.0, 121.4], p  0.008), multivessel disease (2- or
3-vessel disease, HR: 2.2 [IQR: 1.1, 4.5], p  0.021).
In the DES ISR cohort, the independent predictors of
MACE were diabetes mellitus in advanced stage (with
retinopathy, neuropathy, or nephropathy, HR: 6.8 [IQR:
3.1, 15.2], p  0.001), post-procedure residual stenosis
20% (HR: 11.9 [IQR: 2.7, 52.2], p  0.001), and
bifurcation lesion treated with 2 stents (HR: 13.0 [IQR:
1.7, 101.5], p  0.015). Independent predictors of TLR in
the same cohort were post-procedure diameter stenosis
20% (HR: 14.2 [IQR: 3.2, 63.7], p  0.001), diabetes
mellitus in advanced stage (HR: 5.4 [IQR: 2.0, 14.8], p 
0.001), bifurcation lesion treated with 2 stents (HR: 21.3
[IQR: 2.7, 169.2], p  0.004), and the total number of
lesions treated (HR: 4.6 [IQR: 1.5, 14.5], p  0.009).
For the overall cohort (combining BMS and DES
together), similar approaches were performed. For the
multivariate analysis, the treatment groups (BMS vs.
DES) were forced in the model and stepwise procedures
were performed using selected covariates from univariate
R
5)
DES-ISR
(n  355) p Value
0.46
(1,235) 63.67 10.50 (355)
.0) 64.0 (32.0, 85.0)
35) 70.4 (250/355) 0.31
33) 39.4 (140/355) 0.001
5) 15.5 (55/355) 0.001
33) 71.3 (253/355) 0.035
,233) 79.8 (283/355) 0.59
33) 54.1 (192/355) 1.00
1) 5.8 (19/326) 0.003
33) 28.2 (99/351) 0.24
33) 20.0 (71/355) 0.002
33) 20.5 (73/355) 0.001
35) 31.2 (111/355) 0.52
35) 13.0 (46/355) 0.15
) 6.4 (11/173) 0.012
35) 44.2 (157/355) 0.81
m creatinine; DES drug-eluting stent(s); ISR in-stent restenosis;MS-IS
1,23
10.77
28.0, 90
905/1,2
332/1,2
78/1,23
948/1,2
1,000/1
667/1,2
25/1,09
308/1,2
162/1,2
146/1,2
411/1,2
126/1,2
17/732
537/1,2
r serustep. The independent predictors for MACE were
m
p
t
[
ions as i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2
J A N U A R Y 2 0 1 2 : 6 4 – 7 1
Abizaid et al.
Cypher for BMS and DES Restenosis
68moderate-to-severe renal disease, diabetes mellitus, post-
procedure diameter stenosis (residual stenosis) 20%,
ultivessel disease (2 or 3 vessels), pre-dilation, and
revious coronary artery bypass graft. When controlling
hese covariates, the HR of DES versus BMS were 1.1
IQR: 0.7, 1.8], and p  0.605. The independent
Table 2. Procedure Characteristics
Variable
(N  1
N  1
N 
Number of lesions treated
Patients with multiple lesions 10.
Type of restenosis
Focal, 10 mm 5.
Tubular, 10 to 20 mm 38.
Diffuse, 20 mm 55.
Type of DES with restenosis, %
Endeavor
Taxus
Cypher
Xience V/Promus
Others
Lesion length, mm
Mean  SD (N) 22.51
Median (min, max) 20.
Reference vessel diameter, mm
Mean  SD (N) 3.00
Median (min, max) 3.
Lesion located in an SVG 2.
Stents/patient
Mean  SD (N) 1.34
Median (min, max) 1.
Pre-dilation 67.
Post-dilation 38.
Stented length/lesion length per lesion, mm
Mean  SD (N) 1.40
Median (min, max) 1.
Bifurcation 16.
Values are% (n/N) unless otherwise noted. Cypher stent is a product o
Medtronic, Inc. (Minneapolis, Minnesota). Promus and Taxus stents are
Abbott Vascular (Abbott Park, Illinois).
NA nonapplicable; SVG saphenous vein graft; other abbreviat
Table 3. In-Hospital and Long-Term MACE
Event
BMS-ISR
(n  1,235)
DES-ISR
(n  355) p Value
1-year MACE 5.7 (63/1,115) 9.5 (32/336) 0.016
Death 1.4 (15/1,111) 2.1 (7/334) 0.300
MI 2.4 (26/1,100) 3.3 (11/331) 0.300
Ischemia-driven TLR 3.1 (34/1,100) 6.9 (23/331) 0.003
Values are % (n/N).
MACEmajor adverse cardiac event(s); TLR target lesion revascularization; other abbrevi-ations as in Table 1.predictors for TLR were diabetes mellitus, ostial location,
and pre-dilation. When controlling these covariates, the
HR of DES versus BMS was 2.0 [IQR: 1.2, 3.5], with a
significant p value of 0.010.
SR
Patients,
Lesions,
Stents)
DES-ISR
(N  355 Patients,
N  380 Lesions,
N  442 Stents) p Value
380 0.09
1,235) 7.0 (25/355)
,375) 9.2 (35/380) 0.008
1,375) 48.7 (185/380) 0.001
1,375) 42.1 (160/380) 0.001
15 NA
33.8 NA
26.4 NA
1.1 NA
23.7 NA
0.001
0 (1,375) 19.31 11.11 (380)
00.0) 16.0 (4.0, 90.0)
0.71
(1,380) 2.99 0.42 (380)
0.0) 3.0 (2.0, 4.2)
,380) 5.8 (22/380) 0.003
0.008
(1,235) 1.25 0.53 (355)
.0) 1.0 (1.0, 5.0)
1,380) 66.6 (253/380) 0.85
1,604) 48.4 (207/428) 0.001
0.37
(1,326) 1.36 0.50 (368)
2.5) 1.2 (0.3, 5.4)
02) 9.3 (19/203) 0.015
Corporation (Bridgewater, New Jersey). Endeavor stent is a product of
ts of Boston Scientific (Natick, Massachusetts). Xience V is a product of
n Table 1.
Table 4. Definite/Probable ST Distribution According to
Different Time Points
Event
BMS-ISR
(n  1,235)
DES-ISR
(n  355) p Value
Deﬁnite/probable ST 1.2 (13/1,100) 2.4 (8/331) 0.12
Early, 0 to 30 days 0.6 (7/1,229) 0.6 (2/352) 1.00
Acute, 0 to 1 day 0.1 (1/1,233) 0.0 (0/355) 1.00
Subacute, 2 to 30 days 0.5 (6/1,229) 0.6 (2/352) 1.00
Late, 31 to 360 days 0.5 (6/1,097) 1.8 (6/330) 0.04
Values are % (n/N).BMS-I
,235
,380
1,660
1,380
0 (123/
3 (74/1
8 (534/
7 (767/
NA
NA
NA
NA
NA
 12.4
0 (2.0, 1
 0.43
0 (1.5, 1
5 (35/1
 0.65
0 (1.0, 5
1 (926/
7 (621/
 0.75
2 (0.1, 1
2 (98/6
f Cordis
producST stent thrombosis; other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2 Abizaid et al.
J A N U A R Y 2 0 1 2 : 6 4 – 7 1 Cypher for BMS and DES Restenosis
69The relatively low number of stent thrombosis pre-
cluded the assessment of independent predictors of this
event.
Discussion
The main findings of this subanalysis of the e-SELECT
registry are that percutaneous treatment of BMS and
DES ISR with the deployment of SES in routine clinical
practice represents a simple, feasible, and safe approach
with high rate of acute success and relatively low inci-
dence of serious adverse events up to 1-year of clinical
follow-up. Even so, ISR recurrence among patients with
previous DES ISR remains elevated (7%), meaning that
alternative treatment strategies might still be evaluated.
Whereas BMS eliminated acute recoil, abrupt vessel
closure, and chronic negative remodeling, the main mech-
anisms behind balloon angioplasty failure, the deployment
of these metal devices was associated with the occurrence of
exacerbated local “healing” response resulting in an abnor-
mal neointimal tissue proliferation within the stent and
recurrence of ischemic symptoms requiring additional re-
vascularization procedures (12).
Before the introduction of DES, wide varieties of percu-
taneous approaches were tested to treat BMS ISR. Among
them, IVB was the most successful strategy, with pivotal
clinical trials showing promising midterm results (13–15).
However, the widespread use of IVB was limited due to
logistic reasons (mainly the need for complex equipment
Figure 1. Kaplan-Meier Survival-Free Curve of MACE for Patients With
BMS and DES ISR Compared With Those With De Novo Lesion Enrolled in
the Registry
Patients with initial presentation of drug-eluting stent (DES) in-stent reste-
nosis (ISR) had worse 1-year outcomes than did those with de novo or
bare-metal ISR (p  0.001 for both comparisons). BMS  bare-metal
stent(s); LR  logistic regression; MACE  major adverse cardiac event(s);
Pr  p value for the regression model.and a large multispecialty team), radiation safety con-cerns, evidence of late loss of clinical efficacy (the “late
catch-up” phenomenon) (16), and safety issues (late stent
thrombosis) (17).
A
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Figure 2. Kaplan-Meier Survival-Free Curves of Death, MI, and TLR for
Patients With De Novo Lesions, BMS-ISR, and DES-ISR
(A) Death, (B) myocardial infarction (MI), and (C) target lesion revasculariza-
tion (TLR). Treatment of DES ISR resulted in higher TLR rates at 1 year as
compared to those with de novo or bare-metal ISR (p  0.001 for both
comparisons). Abbreviations as in Figure 1.
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70The advent of DES and the demonstration of their
marked suppression of neointimal formation resulting in
very low rates of restenosis in a variety of complex clinical
and angiographic scenarios made these novel devices a
relatively simple and attractive option to treat BMS ISR.
Consequently, the use of DES was tested against and
showed superiority over balloon angioplasty alone (18),
implant of another BMS (19), and intravascular brachyther-
apy (20,21). Of note, the SISR (Sirolimus-Eluting Stent vs.
Brachytherapy in Patients With Bare Metal In-Stent Re-
stenosis) trial randomized 384 patients with BMS ISR to
either DES (Cypher) or IVB (20). At the end of 9 months,
target vessel failure was observed in 21.6% of the patients
treated with IVB and 12.4% in those treated with DES (p
0.02). Similarly, the TAXUS V trial compared 196 patients
with BMS ISR treated with the Taxus stent (Boston
Scientific, Natick, Massachusetts) to 201 patients treated
with IVB (21). At 9 months, patients allocated to the Taxus
arm experienced a reduction of 60% in the need for target
vessel revascularization (p 0.05). Because of these studies,
DES implantation became the first choice of treatment for
BMS ISR.
If the question about the best way to treat BMS ISR was
thus adequately answered, the same could not be said about
DES ISR. Following the growing use of DES in the most
complex scenarios, DES ISR also was increasingly observed
in patients. Intuitively, the deployment of another DES to
treat the restenosis became an option in many centers
worldwide, despite the lack of large randomized controlled
trials attesting the safety and efficacy of this strategy. Lemos
et al. (22) were the first to report the 9-month results of 24
patients with DES ISR treated with Cypher. They observed
a recurrence of restenosis in 18.2% of the cases.
Following this pioneering report, many other series com-
paring different strategies were published from different
centers. Abe et al. (23) published a subanalysis of the
Japanese registry of Cypher (J-Cypher) where they com-
pared the deployment of a Cypher stent versus plain balloon
angioplasty for the treatment of Cypher ISR. At 2 years,
patients treated with another Cypher had significantly less
recurrence of ISR (23.8% vs. 37.7%, p 0.0001), but 2-year
mortality (10.4% in the Cypher vs. 10.8% in the plain
balloon angioplasty, p 0.4) and ST (0.6% for both groups)
did not differ between cohorts.
In the ISAR-DESIRE (Intracoronary Stenting and Angio-
graphic Results: Drug-Eluting Stents for In-Stent Restenosis)
2 trial, Mehilli et al. (24) reported the outcomes of 450
consecutive patients with Cypher ISR randomized (1:1) to
receive either a different DES type (Taxus paclitaxel-eluting
stent) or the same DES. At the end of 1-year follow-up, both
cohorts presented similar rates of death/MI (6.1% for Cypher
vs. 5.8% for Taxus, p  0.86), TLR (16.6% vs. 14.6%, p 
0.52), and stent thrombosis (0.4% vs. 0.4%, p  0.99).
Compared to both series, the present registry included asignificantly larger patient population and presents the lowest
rate of TLR after use of SES for the treatment of DES ISR.
A possible explanation could be the absence of routine
follow-up angiography in the e-SELECT registry, which
reflects the current clinical practice and prevents the oculostenotic
reflex, a frequent cause of unnecessary repeated procedures.
The finding of a higher late ST rate among patients with
previous DES ISR might be explained by the more complex
clinical and angiographic characteristics of this cohort that
included a significantly higher number of patients with
diabetes, longer lesions, higher Charlson comorbidity index,
and renal failure. All these characteristics have been previ-
ously correlated with incremental occurrence of ST (25–28).
Although not fully satisfactory in terms of TLR recur-
rence, to date the deployment of another DES, in particular
a SES, has been the most widely tested and most effective
strategy to treat DES ISR. However, it is important to
consider the mechanisms behind the failure of SES to treat
a DES ISR, because the only independent predictor of TLR
among these patients in the present study was a residual
stenosis 20% at the end of the baseline procedure, most
probably often reflecting stent underexpansion.
Based on this finding, it is imperative to stress again the
importance of adequate stent implantation technique, includ-
ing aggressive stent post-dilation and, when needed, intravas-
cular ultrasound guidance, as a way to optimize acute proce-
dure results and minimize the risk of ISR recurrence.
Study limitations. Although enrolling all consecutive patients
treated with SES was strongly encouraged in all participating
centers, no information was collected on patients treated with
SES but not enrolled in the e-SELECT registry. Also, the use
of other stents than SES during the index procedure was an
exclusion criterion. Both these factors may have contributed to
some degree of selection bias. Some relevant variables, such as
elapsed time to ISR and final dilation pressure, were not
captured in the database, and, therefore, their potential influ-
ence on outcome could not be determined. Potential differ-
ences according to the underlying DES could not be estab-
lished due to small patient cohorts. We monitored the source
data collected in a random sample representing 20% of the
patients enrolled in e-SELECT registry. Although this com-
pares favorably with other recent stent registries, the under-
reporting of adverse events remains a potential limitation. The
follow-up period was only 1 year. Thus, it is possible that the
relative risks of ST are different over a longer period, especially
because compliance with dual antiplatelet therapy would be
expected to drop significantly beyond the 1-year time point.
The lack of an independent core lab to assess angiographic
results might lead to inappropriate assessment of restenosis
type, residual stenosis, and other import angiographic variables
here reported based on visual assessment from the local sites.
Late angiography evaluation was not systematically obtained
and only the visual angiographic analysis obtained at the sites
was available. Finally, we did not compare the use of SES to
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71other contemporary strategies, such as the use of different DES
or drug-coated balloons.
Conclusions
In the challenging scenario of percutaneous treatment of ISR,
use of SES was shown to be feasible, safe, and associated with
an acceptably low recurrence of adverse events (1-year com-
bined MACE rate 10% for both cohorts). However, ISR
ecurrence in patients with DES ISR was relatively high (6.9%)
nd over twice as frequent as with BMS ISR, suggesting that
ther treatment strategies may be needed.
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